Italy Drug Delivery Devices Market: Market Size & Forecast 2026

Italy represents one of the largest and most mature pharmaceutical markets in Europe, with a well-developed medical device sector closely integrated into its broader healthcare ecosystem. The drug delivery devices segment benefits from robust domestic manufacturing capacity, strong research infrastructure, and a regulatory environment governed by the European Medicines Agency (EMA) and the Italian Medicines Agency (AIFA). The market's $123.42 billion valuation in 2025 reflects both the breadth of device categories and the increasing complexity of delivery technologies required for modern biologic and specialty drug formulations. Northern Italy, particularly the Lombardy and Lazio regions, serves as the primary industrial and R&D hub for pharmaceutical and medical device activity.

• •Aligned with EMA and AIFA regulatory frameworks governing drug-device combination products
• •Strong manufacturing base concentrated in Lombardy, Lazio, and Emilia-Romagna regions
• •Robust domestic pharmaceutical industry creates endogenous demand for delivery devices

Italy's demographic profile is a primary structural driver: the country has one of the oldest populations in the world, with over 23% of residents aged 65 and above, creating sustained demand for devices managing age-related chronic conditions. The rising burden of diabetes, respiratory diseases, autoimmune disorders, and cancer increases reliance on self-administration technologies such as prefilled syringes, auto-injectors, and needle-free systems. Expanding public and private healthcare investment, combined with Italy's world-class pharmaceutical manufacturing sector and active role in biosimilar development, amplifies demand for compatible, high-performance delivery systems across both domestic and export markets.

• •Aging population and rising chronic disease prevalence drive long-term device demand
• •Growth in biologic and biosimilar drug pipelines requires compatible advanced delivery platforms
• •Strong domestic pharmaceutical manufacturing ecosystem generates endogenous consumption

The Italian market is broadly segmented across injectable drug delivery (prefilled syringes, pen injectors, auto-injectors), pulmonary delivery (inhalers, nebulizers), transdermal and topical systems, nasal drug delivery, and implantable/infusion technologies. Geographically, Northern Italy, encompassing Lombardy, Piedmont, Veneto, and Emilia-Romagna, dominates market activity, anchored by Milan's concentration of pharmaceutical headquarters, manufacturing facilities, and contract research organizations. Central Italy, particularly Lazio (Rome), hosts significant regulatory, clinical, and institutional research activity, while Southern Italy represents a growing but comparatively smaller segment of the overall market.

• •Lombardy leads in manufacturing volume and pharmaceutical R&D investment
• •Lazio (Rome) is a major center for regulatory affairs and clinical research activity
• •Injectable and pulmonary delivery segments account for the largest revenue share

What are the recent trends and outlook?

Several emerging trends are reshaping the trajectory of Italy's drug delivery devices market. Connected and smart delivery devices, integrating sensors, digital adherence tracking, and data connectivity, are gaining adoption as healthcare systems prioritize patient monitoring and treatment optimization. The ongoing expansion of Italy's biologics and biosimilars pipeline is elevating demand for specialized delivery solutions such as wearable injectors, high-precision auto-injectors, and reconstitution systems. Regulatory incentives tied to digital health innovation, combined with Italy's commitment to EU health technology initiatives, are expected to sustain the market's 7.8% annual growth rate through 2030, with injectable and connected delivery platforms representing the most dynamic subsectors over the forecast horizon.

• •Connected and digitally integrated delivery devices are a fast-growing innovation segment
• •Biosimilars and biologic drug proliferation is elevating demand for specialized delivery platforms
• •EU digital health regulatory alignment and Italy's innovation incentives support sustained market expansion